Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
Endocrine-Related Cancer · 03.06.2024 · 31 (8)
DOI: 10.1530/erc-23-0354 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Endocrine-Related Cancer, erschienen am 03.06.2024. Verfasst von Marcia S Brose und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Piperidines, Quinazolines, Iodine Radioisotopes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The VERIFY study aimed to determine the efficacy of vandetanib in patients with differentiated thyroid cancer (DTC) that is either locally advanced or metastatic and refractory to radioiodine (RAI) therapy. Specifically, VERIFY is a randomized, double-blind, multicenter phase III trial aimed to determine the efficacy and safety of vandetanib in tyrosine kinase inhibitor-naive patients with locally advanced or metastatic RAI-refractory DTC with documented progression (NCT01876784). Patients were randomized 1:1 to vandetanib or placebo. The primary endpoint was progression-free survival (PFS). Secondary endpoints included best objective response rate, overall survival (OS), safety, and tolerability. Patients continued to receive randomized treatment until disease progression or for as long as they were receiving clinical benefit unless criteria for treatment discontinuation were met. Following randomization, 117 patients received vandetanib, and 118 patients received a placebo. Median PFS was 10.0 months in the vandetanib group and 5.7 months in the placebo group (hazard ratio: 0.75; 95% CI: 0.55–1.03; P = 0.080). OS was not significantly different between treatment arms. Common Terminology Criteria for Adverse Events (CTCAE) of grade ≥3 were reported in 55.6% of patients in the vandetanib arm and 25.4% in the placebo arm. Thirty-three deaths (28.2%; one related to study treatment) occurred in the vandetanib arm compared with 16 deaths (13.6%; two related to treatment) in the placebo arm. No statistically significant improvement was observed in PFS in treatment versus placebo in patients with locally advanced or metastatic, RAI-refractory DTC. Moreover, active treatment was associated with more adverse events and more deaths than placebo, though the difference in OS was not statistically significant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
- Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Department of Clinical Oncology, Odense University Hospital, Odense, Denmark.
- Department of Endocrinology, Diabetes and Metabolism and Clinical Chemistry, University Hospital Essen, Essen, Germany.
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, Villejuif, France.
ORCID-Profile: Marcia S Brose, Rossella Elisei, Lori J Wirth, Paolo Caferra
Zitieren
APA
Brose, M. S., Capdevila, J., Elisei, R., Bastholt, L., Führer-Sakel, D., Leboulleux, S., Sugitani, I., Taylor, M. H., Wang, Z., Wirth, L. J., Worden, F. P., Bernard, J., Caferra, P., Colzani, R. M., Liu, S., & Schlumberger, M. (2024). Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. Endocrine-Related Cancer, 31(8). https://doi.org/10.1530/erc-23-0354
Vancouver
Brose MS, Capdevila J, Elisei R, Bastholt L, Führer-Sakel D, Leboulleux S, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. Endocrine-Related Cancer. 2024;31(8). doi:10.1530/erc-23-0354
BibTeX
@article{Brose2024,
author = {Brose, Marcia S and Capdevila, Jaume and Elisei, Rossella and Bastholt, Lars and Führer-Sakel, Dagmar and Leboulleux, Sophie and Sugitani, Iwao and Taylor, Matthew H and Wang, Zhuoying and Wirth, Lori J and Worden, Francis P and Bernard, John and Caferra, Paolo and Colzani, Raffaella M and Liu, Shiguang and Schlumberger, Martin},
title = {Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy},
journal = {Endocrine-Related Cancer},
year = {2024},
volume = {31},
number = {8},
doi = {10.1530/erc-23-0354}
}
EUVIMED